Accelerating Biologic Discovery with Confidence
Mosaic Biosciences is an integrated biologics discovery partner advancing complex antibody and protein therapeutics. Our approach combines antibody discovery, protein engineering, and translational pharmacology to move programs from concept to candidate selection with scientific rigor and speed.
Our Biologic Discovery Solutions
Mosaic delivers integrated discovery programs across antibody engineering, protein science, cell-based screening, and pharmacology supporting progression from target to candidate.
Antibody Discovery & Optimization
Protein Design & Engineering
Protein Sciences & Analytics
Cell-Based Assays
Pharmacology
Why Mosaic for Biologic Discovery
Mosaic integrates advanced antibody libraries, protein engineering, function-first screening, and early developability assessment to accelerate progression from target identification to candidate selection.
End-to-end discovery integration
Concept-to-candidate programs run under one team, without fragmenting your workflow across vendors.
Freedom to operate
Milestone-based, royalty-free access to our proprietary antibody platform, no downstream royalty stacking on your candidates.
Function-first screening strategy
Function-first testing and biophysical characterization are embedded at every stage, not bolted on at the end.
Complex protein expertise
Deep experience engineering difficult targets, bispecifics, membrane proteins, and other structurally complex biologics.
Early developability focus
Developability assessed from day one, catching liabilities before they become late-stage failures.
FHD technology access
Exclusive access to our Atlas™ FHD platform, fully human antibody repertoires with broad epitope coverage.
Leadership with Proven Biologic Discovery Impact
Mosaic’s scientific leadership team has built platforms, advanced clinical candidates, and led discovery programs at leading biotechnology and pharmaceutical companies.
Eric Furfine, PhD
Chief Scientific Officer
Led IPO-financed Phase 3 programs at Eleven Biotherapeutics. Built the Adnectin platform (acquired by BMS). Former VP at Regeneron contributing to Eylea development.
Alexei Kazantsev, PhD
Vice President Protein Design and Engineering
Structural and chemical biology expert. Leads protein engineering and PK optimization at Mosaic. Prior research in RNA and protein structural biology using X-ray crystallography and SAXS.
Tracey Mullen
Chief Strategy Officer
Former SVP Biopharma at Twist Bioscience (post-Abveris acquisition). Former CEO of Abveris. Antibody discovery leadership experience at Biogen and Adimab platform implementation.
Scott Glaser PhD
SVP, Biologics Discovery
30+ years in biologic drug discovery. Former Director of Antibody Therapeutics at Novartis (GNF) and senior leadership at Pfizer and Biogen. Contributor to 50+ discovery programs and co-inventor on 23 US patents.
Start a conversation with our scientific team about your discovery program today